Alembic Pharma successfully completes USFDA inspection for Derma Facility at Karakhadi
Vadodara: Alembic Pharma has announced that the company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Derma Facility located at Karakhadi without any observations.
The inspection was conducted from 6th March, 2023 to 10th March, 2023.
Medical Dialogues team had earlier reported that the Company had received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out at the company's Injectable Facility (F-3) at Karkhadi.
Headquartered in Vadodara, Gujarat, Alembic Pharmaceuticals Limited is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. The company was founded in 1907. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic has a cumulative total of 183 ANDA approvals (160 final approvals and 23 tentative approvals) from USFDA.